Phase 2 Study Begins for German Biopharma's Cancer Drug Candidate

Research Report
  ()
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated. read more >

Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data

Research Report
  ()
Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report. read more >
News Update

Healthcare Solutions Provider to Acquire Medical Software Firm

News Update
  ()
The merger will allow the Canadian company to expand its online technology platform. read more >

Biotech Enters License Agreement to Validate Biomarker as Alternative NASH Diagnostic

Research Report
  ()
The background and justification for the deal was covered in an H.C. Wainwright & Co. report. read more >

Potential Tenbagger Biopharma Displays 'Strong Start to New Year'

Research Report
  ()
A ROTH Capital Partners report discussed the recent trial launch and provided upcoming catalysts for the stock. read more >

Texas-Based Biopharma Gets PDUFA Date for Lead Orphan Disease Asset

Research Report
  ()
An H.C. Wainwright & Co. report covered the potential timeline to market and subsequent estimated revenue for this therapeutic, which addresses a rare disorder in collagen production. read more >

Coverage Initiated on Pharma 'Leveraging Large Markets with Differentiated Products'

Research Report
  ()
A Ladenburg Thalmann report outlined the investment thesis for this Colorado-based life sciences firm. read more >

Coverage Initiated on Vaccine Developer with 'Transformational' Data Expected

Research Report
  ()
A Ladenburg Thalmann report discussed this biotech's late-stage clinical assets in RSV and influenza. read more >

Therapeutics Developer Secures Patents, Continues Phase 3 Trial Planning

Research Report
  ()
An H.C. Wainwright & Co. report provided an update on the Q3/18 activities and achievements of this company targeting NASH. read more >

Analyst: Biopharma Makes 'Right Call' in Stopping Combination Agent in Trial

Research Report
  ()
A Mackie Research Capital Corp. note reviewed recent and upcoming developments in this immunotherapy developer's clinical study. read more >
Expert Investing Ideas

"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


"DRRX intends to start a NASH trial as soon as H1/19."

–Francois Brisebois, Laidlaw & Company


"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Urgent Update on Canadian Health Company Acquisition

Contributed Opinion
  ()
Technical analyst Clive Maund charts the potentially transformative acquisition of a medical software provider in Canada. read more >

Small-Cap Firm Announces Major Medical Technology Acquisition

Contributed Opinion
  ()
Ron Struthers of Struthers Resource Stock Report profiles an innovative medical firm in Canada that just announced the acquisition of a medical technology firm, a move that will expand its reach across Canada. read more >
News Update

Gold Company Announces New Drilling Success at Red Lake Project

News Update
  ()
Results suggest further zones of mineralization on the property. read more >

Coverage Initiated on Tech Firm Servicing Healthcare Industry

Research Report
  ()
Haywood Securities presented the thesis for investment in this company, including its growth drivers and continued focus on acquisition. read more >